227 related articles for article (PubMed ID: 8275889)
1. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms].
Lejoyeux M; Gorwood P; Stalla-Bourdillon A; Adès J
Encephale; 1993; 19(1):17-21. PubMed ID: 8275889
[TBL] [Abstract][Full Text] [Related]
2. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
3. [Translation and validation of a French version of the Young Mania Rating Scale (YMRS)].
Favre S; Aubry JM; Gex-Fabry M; Ragama-Pardos E; McQuillan A; Bertschy G
Encephale; 2003; 29(6):499-505. PubMed ID: 15029084
[TBL] [Abstract][Full Text] [Related]
4. Side effects during long-term treatment with depot antipsychotic medication.
Cookson JC
Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
[TBL] [Abstract][Full Text] [Related]
5. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
Llorca PM; Wolf MA; Lançon C; Bougerol T
Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
[TBL] [Abstract][Full Text] [Related]
6. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
7. An open trial of buspirone added to neuroleptics in schizophrenic patients.
Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
[TBL] [Abstract][Full Text] [Related]
8. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
9. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
10. [Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
Klieser E; Lehmann E; Tegeler J
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():14-7. PubMed ID: 1683333
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Yen YC; Lung FW; Chong MY
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
[TBL] [Abstract][Full Text] [Related]
12. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
Bransgrove LL; Kelly MW
Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
[TBL] [Abstract][Full Text] [Related]
13. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
[TBL] [Abstract][Full Text] [Related]
14. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
15. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders.
Kim JH; Jung HY; Kang UG; Jeong SH; Ahn YM; Byun HJ; Ha KS; Kim YS
Mov Disord; 2002 Nov; 17(6):1354-9. PubMed ID: 12465082
[TBL] [Abstract][Full Text] [Related]
16. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
17. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
18. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
19. Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics.
Weisbard JJ; Pardo M; Pollack S
Psychopharmacol Bull; 1997; 33(1):119-22. PubMed ID: 9133762
[TBL] [Abstract][Full Text] [Related]
20. A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.
Mendlewicz J; de Bleeker E; Cosyns P; Deleu G; Lotstra F; Masson A; Mertens C; Parent M; Peuskens J; Suy E
Acta Psychiatr Scand Suppl; 1990; 358():138-41. PubMed ID: 1978474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
